On January 3, 2022, the U.S. Food and Drug Administration (FDA) amended the emergency use authorization (EUA) for the Pfizer-BioNTech COVID-19 vaccine to include:
- Authorization of a booster dose for people 12 and older.
- A shortened interval of 5 months between a booster dose and completion of the primary vaccine series for people 12 and older.
- A third primary series dose allowed for certain immunocompromised children 5 to 11 years old.
The Texas Health and Human Services Commission (HHSC) allows pharmacy benefit coverage of the Pfizer-BioNTech COVID-19 vaccine in compliance with the expanded use authorized by the FDA.
Email VDP-Formulary@hhsc.state.tx.us with questions or comments.